The FDA has approved Kedrion Biopharma’s Qivigy, a 10% IV immunoglobulin therapy, for treating adults who have primary ...
The product is expected to be available in early 2026. The Food and Drug Administration (FDA) has approved Qivigy (immune globulin intravenous [IV], human-kthm) 10% solution for the treatment of ...
Chronic malaria exposure has been proposed to modulate immune function, but its long-term effects on antibody-mediated responses to unrelated pathogens remain poorly defined. Whether these effects ...
Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Breakthrough method turns ‘cold’ tumors into immune targets, raising hope for lasting cancer control - Anadolu Ajansı ...
About 90% of people in the Lower Mainland of British Columbia have detectable antibodies against measles, indicating robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback